Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia.
Cell Host Microbe
; 29(12): 1738-1743.e4, 2021 12 08.
Article
em En
| MEDLINE
| ID: mdl-34861167
ABSTRACT
Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines Pfizer/BioNTech, AstraZeneca, Sputnik V, and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant receptor binding domain (RBD) proteins revealed marked differences in vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. The Alpha variant caused 97% of infections in Mongolia in June and early July 2021. Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control COVID-19 in Mongolia and worldwide.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vacinação em Massa
/
Vacinas contra COVID-19
/
SARS-CoV-2
/
COVID-19
/
Vacina BNT162
/
ChAdOx1 nCoV-19
/
Anticorpos Antivirais
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article